RP3

AXP000079.1 · Oncolytic virus

Platform
HSV-1 (RH018A strain, ICP34.5- ICP47-)
Originator
Replimune
Sponsor
Replimune

Names

NameTypeSource
RP3 ambiguouspreferred name, codecurator, ncit

Virus

Role
Oncolytic
Family
Orthoherpesviridae
Virus
herpes simplex virus 1 (NCBI Taxonomy 10298)
Strain
RH018A
Replication
conditionally replicating
Modifications
RL1 (ICP34.5) and US12 (ICP47) deleted
Transgenes
CD40LG, TNFSF9, GALV-GP R-, anti-CTLA-4 antibody
Route
intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C179624

Approvals

No regulatory approval recorded.

Clinical trials (3)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT05743270Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHNWithdrawnPhase 22024-01-302026-03-010Locally Advanced Head and Neck Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma; Squamous Cell Carcinoma of Head and Neck
NCT05733611RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRCTerminatedPhase 22023-06-292025-08-185MSS; Refractory Metastatic Colorectal Cancer; pMMR
NCT04735978Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid TumoursActive not recruitingPhase 12020-12-292026-11-30123Advanced Solid Tumor

Recent changes

No changes recorded in its trials yet.

Notes

RP2 backbone with CD40L and 4-1BBL in place of GM-CSF, plus the anti-CTLA-4 molecule. First patient dosed in a phase 1 in 2021; phase 2 NCT05733611 terminated.

How to cite

RP3 (AXP000079.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000079.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.